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Introduction
Global healthcare systems are rapidly having to change and 
adapt in the face of the COVID-19 pandemic. At a more 
individual level, neurologists are being faced with complex 
decisions regarding the risk of infection in specific patient 
groups, and in particular those receiving immunosuppres-
sant or immunomodulatory therapy. One such important 
patient group is those individuals with multiple sclerosis 
(MS) receiving disease-modifying therapies (DMTs).
It has previously been established that people with MS 
(PwMS) have an increased risk of infections compared 
with the general population. These infections can lead to 
significant morbidity and may also contribute to relapses 
and a worsening of neurological symptoms. First-generation 
DMTs such as interferon-beta (IFN-β) or glatiramer acetate 
(GA) are not thought to be associated with a significantly 
increased risk of infection, although more efficacious second 
generation DMTs have demonstrated a higher risk profile. 
However, the majority of these observations are derived 
from clinical trials of MS DMTs which, because of restricted 
inclusion criteria and short-term follow-up, may underes-
timate the overall risk. Real-world experience with longer 
term follow-up in representative patient groups may be nec-
essary to achieve a more accurate picture, although these 
data are currently limited. In the context of the evolving 
COVID-19 pandemic, it has become particularly important 
to understand these risks to make informed decisions regard-
ing treatment and to be able to communicate this informa-
tion effectively to patients. In all cases any increased risk of 
infection and associated morbidity will need to be carefully 
balanced against risks of stopping treatment and rebound 
disease activity.
From an historical perspective, it is also interesting to 
note that the coronavirus family has been previously investi-
gated for a potential association with MS, and more recently 
has been utilised to make a mouse model of the disease 
(coronavirus-induced encephalomyelitis). We should also 
not assume that effects of COVID-19 infection, and in par-
ticular the rarer but more serious secondary hyperinflamma-
tion syndrome, should necessarily be worsened in PwMS on 
DMTs and they may even be protective; inhaled treatment 
with interferon-beta as well as Fingolimod are currently 
under investigation as a potential treatment for COVID-19 
infection. Nevertheless, understanding the risk of infection 
in MS patients remains important, especially with regard to 
decisions concerning therapeutic management.
In this month’s journal club, we consider three papers 
relevant to the risk of infection in patients with MS. These 
studies highlight the general increased risk of infections 
in PwMS and those of specific treatments. Although data 
from many DMTs are considered in these studies, there are 
some—notably alemtuzumab and ocrelizumab that are not 
currently captured by these predominantly registry-based 
studies. In the meantime, many national neurology associa-
tions as well as MS charitable bodies have issued guidance 
with regard to the use of all DMTs in light of the current 
pandemic and are a useful practical resource for neurolo-
gists to review.
Infections in patients diagnosed 
with multiple sclerosis: a multi‑database 
study
This study aimed to characterise the infection risk of 
patients with MS compared with a cohort of patients 
without MS. The authors utilised two large databases, the 
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United States Department of Defense (US-DOD) health 
care system and the United Kingdom’s Clinical Practice 
Research Datalink GOLD (UK-CPRD). The US-DOD is 
composed of data from members of the US-DOD, retirees 
and dependents. The UK-CPRD is a large, prospectively 
collected medical record database from over 500 general 
practices.
Patients with a first diagnosis of MS were identified 
between the years 2001 and 2016 (UK-CPRD, n = 6932) 
and 2004 and 2017 (US-DOD, n = 8695). MS patients 
were matched to patients without MS based on age, sex, 
date of MS diagnosis/matched date, and location (US-
DOD; 86,934, UK-CPRD 68,526). Estimated incidence 
rates (IRs) and incidence ratios (IRRs) with 95% confi-
dence intervals of the first of each infection outcome were 
calculated. MS patients in the US-DOD had received at 
least one MS DMT, but information on treatment in the 
UK-CPRD was lacking.
The incidence of infection was higher in MS patients 
compared with non-MS patients: US-DOD (IRR 1.76; 95% 
CI 1.72–1.80) and UK-CPRD (IRR 1.25; 95% CI 1.21–1.29). 
Compared to patients without MS, the rate of infections 
causing hospitalisation in MS patients was higher in both 
databases (US-DOD IRR 2.43; 95% CI 2.23–2.63 and UK-
CPRD IRR 2.00; 95% CI 1.84–2.17). With regard to rates of 
infection by site, MS patients had higher rates of urinary and 
kidney infections compared with non-MS patients (US-DOD 
IRR 1.88; 95% CI 1.81–1.95 and UK-CPRD IRR 1.97; 95% 
CI 1.86–2.09), with female MS patients having a higher risk. 
Pneumonia and influenza risk were increased in MS patients 
in the US-DOD, but not the UK-CPRD while skin and fun-
gal infections were elevated across both databases. Viral 
infections were slightly increased in the US-DOD cohort, 
but not the UK-CPRD. Respiratory and throat infections rate 
were slightly elevated in the MS group. There was a slightly 
elevated rate of any opportunistic infections (US-DOD IRR 
1.54; 95% CI 1.48–1.61 and UK-CPRD IRR 1.35; 95% CI 
1.26–1.45), the majority of which were candidiasis and her-
pes viruses. IRs of meningitis and encephalitis, tuberculosis, 
hepatitis B and hepatitis C were low across both databases. 
Patients using monoclonal antibodies (identified in the US-
DOD) had a lower rate of infection compared to all MS 
patients but the rate of hospitalised infections was higher.
Comment This study utilised large databases with a 
long follow-up time. MS patients were demonstrated to be 
at an increased risk generally of infections, and of infec-
tions requiring hospitalisation. It is pertinent to observe that 
because of lack of available data, this study was unable to 
focus on the risk of infection with individual DMTs or in MS 
patients not on treatment. Other limitations due to lack of 
data included the inability to account for relevant covariates 
and being unable to determine if some infections required 
hospitalisation.
Persson et al. Mult Scler Relat Disord. 2020;41:101–982. 
https ://doi.org/10.1016/j.msard .2020.10198 2. [Epub ahead 
of print].
Infection risks among patients with multiple 
sclerosis treated with fingolimod, 
natalizumab, rituximab, and injectable 
therapies
This registry study aimed to examine the risk of serious 
infections associated with routinely used MS DMTs as well 
as rituximab, which is commonly used in this population. 
The Swedish MS Register was utilised to identify all patients 
with relapsing–remitting MS and who started a treatment 
with IFN-β and GA, fingolimod, natalizumab, or rituximab 
between 2011 and 2017. Five comparator patients were 
matched for each MS patient from the general population 
by age, sex and region. The main outcome was identified 
as the time until the first serious infection (hospitalisation 
caused by the infection). Less severe infections were identi-
fied by prescriptions of any systemic antibiotic and antiviral 
medication for herpetic infections. Cox proportional hazard 
models were used to estimate hazard ratios. As participants 
could contribute data to multiple treatment cohorts, robust 
95% confidence intervals were calculated.
A total of 8600 treatment episodes were included from 
a total of 6421 patients (female 71.9%; 2217 initiations of 
IFN-β and GA, 1535 fingolimod, 1588 natalizumab, and 
3260 rituximab). The mean time (years) receiving DMTs 
was as follows: IFN-β and GA, 2.1; fingolimod, 7; natali-
zumab, 2.5; rituximab, 2.0. The crude serious infection inci-
dence rate was higher across all MS patients compared to 
the general population. Before adjusting for differences in 
patient characteristics, the incidence rate of serious infec-
tions was similar for patients treated with IFN-β and GA 
(incidence rate, 8.9 [95% CI 6.4–12.1] per 1000 person-
years), and natalizumab (11.4 [95% CI 8.3–15.3] per 1000 
person-years). This was lower than the rate for fingolimod 
(14.3 [95% CI 10.8–18.5] per 1000 person-years) and 
rituximab-treated patients (19.7 [95% CI 16.4–23.5] per 
1000 person-years). In the most adjusted model taking into 
account potential confounders and when comparing against 
IFN-β and GA, only rituximab had a statistically significant 
increased risk (HR, 1.70 [95% CI 1.11–2.61]) although point 
estimates for fingolimod and natalizumab were still greater 
than 1.00 (HRs, 1.30 [95% CI 0.84–2.03] and 1.12 [95% CI 
0.71–1.77], respectively). Rituximab and natalizumab had 
the highest rate of antibiotic use. The use of antiviral drugs 
was significantly higher in patients taking natalizumab and 
fingolimod when compared with either IFN-β and GA or 
rituximab. After adjustment, the rate of herpetic infections 
was similar when comparing rituximab with IFN-β and GA.
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Comment This large cohort study provides further sup-
port that patients with MS being treated with DMTs are at a 
generally increased risk of infection, with rituximab associ-
ated with the highest rate of serious infections. The authors 
note that because of the non-availability of primary care 
data in the national registries, most minor infections were 
not included in the study. Data were also lacking on several 
potential confounders including body mass index, smoking 
status, and varicella vaccination status.
Luna et  al. JAMA Neurol. 2019 Oct 7. https ://doi.
org/10.1001/jaman eurol .2019.3365. [Epub ahead of print].
Disease‑modifying drugs for multiple 
sclerosis and infection risk: a cohort study
This paper investigated the association between MS DMTs 
and risk of infections in a population-based retrospective 
cohort study. The primary study outcome was the hazard of 
infections, based on physician claims with secondary out-
comes related to the risk of infection-related hospital admis-
sions and individual infections. A proportional means model 
for recurrent events was used to examine the association 
between DMT exposure and infections. All analyses were 
adjusted for sex, age, socio-economic status and co-morbidi-
ties. DMTs were grouped into first generation (IFN-β or GA) 
or second generation (natalizumab, fingolimod, or dimethyl 
fumarate). Of note, no patients were taking teriflunomide, 
alemtuzumab or the generic beta-interferon-1b (Extavia).
The authors identified 6793 MS patients (73.6% female). 
Mean age at index demyelinating event was 45.4 years and 
mean follow-up 8.5 years. During the study period, 1716 
patients (25.3%) were prescribed at least one DMT. Patients 
prescribed ≥ 2 different DMT groups totalled 458 (6.7%). 
The patients in each group were as follows: IFN-β (1386, 
20.4%), GA (656, 9.7%), natalizumab (100, 1.5%), oral 
DMTs (98, 1.4%)—fingolimod (61, 0.9%), dimethyl fuma-
rate (40, 0.6%). Exposure to any DMT, first generation DMT 
(either grouped or as IFN-β or GA separately) was not asso-
ciated with an altered hazard (aHR) for an infection-related 
physician claim relative to no DMT. Conversely, an elevated 
aHR was observed with the grouped second generation 
DMTs (aHR 1.47; 95% CI 1.16–1.85) although this asso-
ciation was only significant for natalizumab (aHR 1.59; 95% 
CI 1.19–2.11) when assessed separately. In comparison to 
first generation DMTs, the second generation drugs showed 
a 53% greater hazard for infection (aHR 1.53; CI 1.21–1.95). 
Infection-related hospitalisation was not significantly asso-
ciated with any DMT group or class of drug compared to 
unexposed patients or when second generation DMTs were 
compared with first generation drugs. When assessing asso-
ciations with individual infections, exposure to any DMT or 
any first generation DMT was associated with a lower hazard 
of pneumonia compared with no DMT exposure. Exposure 
to second generation DMTs was associated with a 58% and 
68% increased hazard of an upper respiratory infection when 
compared to no exposure or first generation drug exposure, 
respectively. Natalizumab was the only second generation 
drug assessed separately and was associated with a higher 
hazard of an upper respiratory tract infection compared to 
no exposure (aHR 1.77; 95% CI 1.26–2.49).
Comment In this study, exposure to a second generation 
DMT was associated with an increase in the risk of infec-
tion, particularly with regard to natalizumab. First genera-
tion DMTs were not associated with an increased risk. Of 
note, IFN-β was associated with a lower risk of pneumonia, 
which the authors speculate could be due to its anti-viral 
effect. The reason for the increased risk of upper respiratory 
tract infections with second generation DMTs, and in par-
ticular natalizumab is unknown. It is acknowledged that the 
relatively small number of patients taking second generation 
DMTs may have limited the detection of differences.
Wijnands et  al. J Neurol Neurosurg Psychiatry. 
2018;89:1050–1056.
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